Share on StockTwits

Karyopharm Therapeutics (NASDAQ:KPTI) Insider Sharon Shacham unloaded 20,000 shares of Karyopharm Therapeutics stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $41.76, for a total transaction of $835,200.00. Following the transaction, the insider now directly owns 908,963 shares in the company, valued at approximately $37,958,295. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Karyopharm Therapeutics (NASDAQ:KPTI) traded down 0.26% on Thursday, hitting $42.59. 337,670 shares of the company’s stock traded hands. Karyopharm Therapeutics has a one year low of $15.50 and a one year high of $47.98. The stock has a 50-day moving average of $28.81 and a 200-day moving average of $29.98. The company’s market cap is $1.268 billion.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Wednesday, May 7th. The company reported ($0.46) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.47) by $0.01. On average, analysts predict that Karyopharm Therapeutics will post $-2.03 earnings per share for the current fiscal year.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.